Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report

Table 1 Summary of the main clinicopathologic and molecular characteristics of squamous cell carcinoma cases with T790M mutation reported in the literature to date[10-17]

Case ID	Baseline							Targeted therapy	Treatment response	Progression						Ref.
	Age / sex	Smoker	Stage	Morphology	Sampling method	Anatomic site	EGFR mutation			Progression time (mo)	Sampling method	Anatomic site	Morphology	EGFR mutation	3rd generation TKI
1	63/F	Never	IV	ADC	PE	RUL	WT1	Erlotinib	PR	22	B	RUL	SCC	L858R + T790M	No	Bugano et al[11]
2	NA	NA	IV	SCC	B	NA	Exon 19 deletion	Erlotinib	NA	10	B	NA	SCC	Exon19-deletion + T790M	NA	Masago et al[10]
3	48/F	Never	IV	SCC	B	RUL	p.L747_P753>S	Gefitinib	PD	2	B	RUL	SCC	Exon19-deletion + T790M	No	Graziano et al[13]
4	70/F	Never	IV	SCC	B	LUL	L858R	Gefitinib	SD / PR2	4	B	Liver	SCC	L858R + T790M	No	Graziano et al[13]
5	64/F	Never	IV	ADC	B	RL	L858R+T790M	Gefitinib	SD	10	B	RL	SCC	L858R + T790M	Rociletinib	Haratani et al[17]
6	74/F	Former	IV	ADC	B	LL	L858R	Gefitinib	PR	10	B	LL	SCC	L858R + T790M	No	Jukna et al[14]
7	79/F	Never	IV	ADC	PE	RLL	p.E746_A750del	Gefitinib	PR	15	B	RL	SCC	p.E746_A750del + T790M	No	Jukna et al[14]
8	52/M	Former	IA	ADC	EB	LUL	L858R	Gefitinib	SD	12	B	Pleura	SCC	L858R + T790M	No	Ding et al[12]
9	53/M	Former	IIIA	SCC	B	NA	T790M	NA	NA	NA	NA	NA	NA	NA	NA	Lai et al[15]
10	65/M	Never	IB	SCC	B	NA	T790M	NA	NA	NA	NA	NA	NA	NA	NA	Lai et al[15]
11	50/F	Never	IIA	SCC	B	NA	T790M	NA	NA	NA	NA	NA	NA	NA	NA	Lai et al[15]
12	71/F	Current	NA	SCC	EB	NA	T790M	NA	NA	NA	NA	NA	NA	NA	NA	Ou et al[16]
13	60/F	Current	NA	SCC	EB	NA	T790M	NA	NA	NA	NA	NA	NA	NA	NA	Ou et al[16]
14	72/M	Current	NA	SCC	EB	NA	T790M	NA	NA	NA	NA	NA	NA	NA	NA	Ou et al[16]
15	63/M	Former	IV	SCC	B	RLL	Exon 19 deletion	Gefitinib/erlotinib	PR / SD3	8	B	RLL	SCC	p.E746_A750del + T790M	Osimertinib	Current article

¹Low cellularity in cytological samples.

²SD In the lung and PR in liver metastases.

³PR to gefitinib and SD to erlotinib. ADC: Adenocarcinoma; B: Biopsy; EB: Excisional biopsy; LL: Left lobe; LUL: Left upper lobe; NA: Not available; PE: Pleural effusion; PD: Progression disease; PR: Partial response; RL: Right lobe; RLL: Right lower lobe; RUL: Right upper lobe; SD: Stable disease; SCC: Squamous cell carcinoma.